Figure 5 | Scientific Reports

Figure 5

From: Treatment with fibroblast growth factor 19 increases skeletal muscle fiber size, ameliorates metabolic perturbations and hepatic inflammation in 5/6 nephrectomized mice

Figure 5

FGF19 reduces hepatic metabolic inflammation in CKD mice. Relative mRNA expression of (A) Foxo1 (B) Myd88 (C) Mcp1 (D) Il-6 (E) Tnfα and (F) Il-1 β in Sham and CKD mice after FGF19 or vehicle treatment. Tbp (TATA-Box Binding Protein) was used as reference gene to normalize the results. Results are expressed as the ratio of target mRNA levels to housekeeping gene mRNA levels and normalized to the levels in Sham. Data are expressed as mean ± SEM for n = 13–15 animals in each group. Statistical analysis was done using a one-way ANOVA test *p < 0.05, **p < 0.01, ***p < 0.001. Abbreviation: CKD: chronic kidney disease, Foxo1: Forkhead box protein O1, Il: interleukine Mcp1: monocyte chemoattractant protein 1, Tnfα: Tumor Necrosis Factor alpha, n.s., not significant.

Back to article page